AnnaLynn Williams, PhD

AnnaLynn Williams, PhD

  • Postdoctoral Research Associate

Departments

Education

BA - University of Rochester (2008)
MS - State University of New York at Buffalo (2013)
PhD - University of Rochester School of Medicine and Dentistry (2019)

Research Interests

  • Neurocognitive and psychosocial late effects of childhood cancer
  • Adolescent and young adult cancer outcomes and survivorship
  • Molecular and genetic epidemiology

Current Research Projects

  • Accelerated aging and aging-related biomarkers and their association with neurocognitive functioning in survivors of childhood cancer
  • Identification of novel biomarkers of neurocognitive toxicity in long-term survivors of Hodgkin lymphoma
  • Association of chronic health conditions with neurocognitive functioning in adult survivors of childhood cancer

Contact Information

AnnaLynn Williams, PhD Epidemiology and Cancer Control MS 735 St. Jude Children's Research Hospital 262 Danny Thomas Place Memphis, TN 38105-3678

Selected Publications

Williams AM, Cole PD. Biomarkers of cognitive impairment in pediatric cancer survivors. J of Clin Onc. 2021 (in press).

Williams AM, Cheung YT, Hyun G, Liu W, Ness KK, Ehrhardt MJ, Mulrooney DA, Bhakta N, Banerjee P, Brinkman T, Green DM, Chemaitilly W, Huang IC, Srivastava DK, Hudson MM, Robison LL, Krull KR. Childhood neurotoxicity and brain resilience to adverse events during adulthood. Ann Neuro 2021 (in press).

Janelsins MC, Heckler CE, Peppone LJ, Ahles TA, Mohile SG, Mustian KM, Palesh O, O’Mara AM, Minasian LM, Williams AM, Magnuson A, Geer J, Dakhil SR, Hopkins JO, Morrow GR. Longitudinal trajectory and characterization of cancer-related cognitive impairment in a nationwide cohort study. J Clin Oncol Sep 21;36(32):JCO2018786624, 2018.

Kerns SL, Fung C,  Monahan PO, Ardeshir-Rouhani-Fard S, Abu Zaid MI, Williams AM, Stump T, Sesso HD, Feldman DR, Hamilton RJ, Vaughn D, Beard C, Huddart R, Kim J, Kollmannsberger C, Sahasrabudhe D, Cook R, Fossa SD, Einhorn L, Travis LB, Platinum Study Group. Cumulative burden of morbidity among testicular cancer survivors after standard cisplatin-based chemotherapy: a multi-institutional study. J Clin Oncol May 20;36(15):1505-1512, 2018.

Williams AM,  Shah R, Shayne M, Huston A, Krebs M, Murray N, Thompson B,  Doyle K, Korotkin J, van Wijngaarden E, Hyland S, Moynihan J, Cory-Slechta D, Janelsins MC. Association between inflammatory markers and cognitive function in breast cancer patients. J Neuroimmunol Jan 15;314:17-23, 2018.

Fung C, Sesso HD, Williams AM, Kerns SL, Monahan P, Abu Zaid M, Feldman DR, Hamilton RJ, Vaughn DJ, Beard CJ, Kollmannsberger C, Cook R, Althouse S, Ardeshirrouhanifard S, Lipshults SE, Einhorn LH, Fossa SD, Travis LB,  Platinum Study Group. A multi-institutional assessment of adverse health outcomes among North American testicular cancer survivors after modern cisplatin-based chemotherapy. J Clin Oncol Apr 10;35(11):1211-1222,2017 .

Williams AM, Zent CS, Janelsins MC. What is known and unknown about chemotherapy-related cognitive impairment in patients with haematological malignancies and areas of needed research. Br J Haematol Sep;174(6):835-846, 2016.

Williams AM, Janelsins MC, van Wijngaarden E. Cognitive function in cancer survivors: analysis of the 1999-2002 National Health and Nutrition Examination Survey. Support Care Cancer May;24(5):2155-2162, 2016.

Fung C, Fossa SD, Williams AM, Travis LB. Long-term morbidity of testicular cancer treatment. Urol Clin North Am Aug;42(3):393-408, 2015.

Last update: June 2021

Close
Close